Article

Rotator cuff pain linked with tear size progression

The risk of symptom progression for asymptomatic rotator cuff tears after a short-term follow-up interval is substantial.

The risk of symptom progression for asymptomatic rotator cuff tears after a short-term follow-up interval is substantial. Pain development is associated with tear size progression (enlargement of full-thickness tears and conversion of partial-thickness to full-thickness tendon defects).

Mall and colleagues monitored 195 patients who had an asymptomatic rotator cuff tear. Both shoulders were evaluated annually (ultrasonography, radiography, clinical assessment) for tear size, tissue degeneration, shoulder joint kinematics, and shoulder function.

A total of 44 patients had new pain in the asymptomatic shoulder at an average of 1.93 years into the study. The onset of pain was consistently associated with a significant increase in the size of the tear: 40% of partial-thickness tears progressed to full-thickness, and 18% of full-thickness tears increased by more than 5 mm. Tears were significantly wider, but not longer, in the symptomatic versus the asymptomatic patients. Patients who became symptomatic during the study also had larger tears at baseline than those who remained pain-free.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.